Disseminating antibiotic resistance rendered by bacteria against the widely used β−lactam antibiotics is a serious concern in the public health care. Development of inhibitors for drug-resistant β−lactamase enzymes is vital to combat this rapidly escalating problem. Recently, the Food and Drug Administration has approved a non-βlactam inhibitor called avibactam for the treatment of complicated intra-abdominal and urinary tract infections caused by drug-resistant Gram-negative bacteria. This work sheds light on the molecular origin of the inhibitory effect of avibactam against drugresistant CTX-M variant of Class-A β-lactamase. Especially, we probed the structural evolution, dynamical features and energetics along the acylation and the deacylation reaction pathways through reliable enhanced sampling molecular dynamics methods and free energy calculations. We scrutinize the roles of active site residues, the nature of the carbonyl linkage formed in the inhibitor-enzyme covalent intermediate and other structural features of the inhibitor molecule. While unraveling the reasons behind the inhibition of all the deacylation routes, this study explains various experimental 1 structural and kinetics data, and paves the way to design new inhibitors based on the β-lactam framework. 1 Introduction β-Lactam antibiotics are antibacterials that are routinely used to inhibit the bacterial cellwall synthesizing enzymes known as penicillin binding proteins (PBPs). It is now well established that their clinical efficacy is progressively deteriorating due to the emergence of drug-resistance in bacteria, primarily associated with their expression of β-lactamases. 1,2 These enzymes hydrolyze β-lactam antibiotics in an efficient manner, preventing the drug molecules to react with PBPs. Four major classes of β-lactamases have been identified: A, B, C and D. 3 Among them, classes A, C and D β-lactamases use their active site serine residue for the catalysis, while class B β-lactamase employs either single zinc ion, or two zinc ions. Here, we focus on class-A serine β-lactamases (ABL). This particular class of β-lactamase includes extended-spectrum β-lactamases (such as SHV, TEM and CTX-M)and serine carbapenemases (for e.g. KPC), that are largely responsible for major outbreaks of antibiotic resistance. 1,4,5 Mechanistically, the inactivation of β-lactam antibiotics by A, C and D β-lactamases occurs through two distinct chemical steps. In the first step (viz. acylation), the βlactam drug reacts with the active site serine, resulting in the formation of a covalent drug-enzyme intermediate, which undergoes further hydrolysis (deacylation) in the next step and dissociates from the active site; see Figure 1. To restore the efficacy of βlactam antibiotics, they are often prescribed in combination with slowly deacylating βlactamase inhibitors. Amoxicillin-clavulanate, ticarcillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam are some generally prescribed combinations of antibiotics and inhibitors. 6,7 These β-lactamase inhibitor...